Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies

Published on :

Leidos’s New Virtual Biotech Startup ‘ExGloH’ Targets Cancer and Infectious Diseases with Improved T Cell Therapies Leidos’s ExGloH Leverages Entrepreneurial Science and Industry-Leading Support Infrastructure to Improve Global Health June 4, 2019 The seed for Leidos’s newest division—and virtual startup biotech—Explorations in Global Health (ExGloH) was planted nearly 20 years ago. In 2000, Leidos secured [….]

NextCure files for $92M IPO to advance Cancer Immunotherapy Pipeline

Published on :

NextCure files for $92M IPO to advance Cancer Immunotherapy Pipeline April 29, 2019 NextCure, a clinical-stage biotech in Beltsville, MD developing cancer immunotherapies, announced the terms for its IPO that could raise up to $92M by offering 5M common shares at $14 – $16. The company has applied to trade on NASDAQ under the symbol, [….]

4 Vaccine and Immunotherapy Companies in Maryland That Are Redefining the Capabilities of Modern Medicine

Published on :

4 Vaccine and Immunotherapy Companies in Maryland That Are Redefining the Capabilities of Modern Medicine Maryland’s World Leading Vaccine Hub Showcased at Fourth Annual MTC Life Science Breakfast January 22, 2019 It might be cold and snowy across the DMV, but one thing is for sure—vaccine and immunotherapy companies are hot in the BioHealth Capital [….]

Q&A with Immunomic’s Teri Heiland, PhD: What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy

Published on :

Q&A with Immunomic’s Teri Heiland, PhD What the ‘UNITE’ Technology Platform Could Mean for the Future of Immunotherapy September 25, 2018   Teri Heiland, Ph.D. is the Senior Vice President of Research and Development, and Co-founder, at Immunomic Therapeutics, Inc., a clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. [….]